Daurismo

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Daurismo is a prescription medication used to treat acute myeloid leukemia (AML). Do not chew, divide, or break Daurismo tablets. Swallow tablets whole.

Daurismo Overview

Reviewed: December 2, 2018
Updated: 

Daurismo is a prescription medicine that is used with the medicine cytarabine to treat adults with newly-diagnosed acute myeloid leukemia (AML). 

Daurismo belongs to a group of anticancer drugs called hedgehog pathway inhibitors. These work by stopping a protein responsible for cell growth signal transduction. In cancer, the signaling pathway is constantly on, leading to tumor growth. Daurismo allows this signaling to be blocked and stops cancer growth.

This medication comes in tablet form and is taken once daily, with or without food. Do not chew, divide, or break Daurismo tablets. Swallow tablets whole.

Common side effects include low red blood cell and platelet counts, shortness of breath and bleeding. Daurismo can cause extreme tiredness. Do not drive or operate heavy machinery until you know how Daurismo affects you.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Daurismo Drug Class

Back to Top

Daurismo is part of the drug class:

Daurismo FDA Warning

Back to Top

Warning: Embryo-Fetal Toxicity

See full prescribing information for complete boxed warning.

  • Daurismo can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. Daurismo is embryotoxic, fetotoxic, and teratogenic in animals.

  • Conduct pregnancy testing in females of reproductive potential prior to initiation of Daurismo treatment. Advise females of reproductive potential to use effective contraception during treatment with Daurismo and for at least 30 days after the last dose.

  • Advise males of the potential risk of exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with Daurismo and for at least 30 days after the last dose to avoid potential drug exposure.